The UK’s Department of Health (DoH) has said that the ‘vast majority’ of prescriptions in the country are not subject to supply problems.
UK’s DoH says most medicines do not experience shortages
Home/Pharma News | Posted 01/07/2016 0 Post your comment
The response from the DoH came in reply to a 9 June 2016 letter from the All-Party Pharmacy Group (APPG), which called for swift action in reducing harm caused by medicine shortages.
In its letter the APPG pointed to the results of its survey of pharmacists and doctors, which showed that medicines shortages continue to occur.
The survey found that 56% of pharmacists and 37% of doctors were ‘almost certain’ to have been out of stock of a medicine or prescribed a medicine that was out of stock once a day over the last six months. While 48% of community pharmacists and 42% of GP practices were spending between 21 and 50 hours a month dealing with medicines shortages. Time that the APPG says could be better spent ‘diagnosing, treating and supporting patients’.
The survey, which was conducted earlier in 2016, in conjunction with North of England Commissioning Support (NECS), also highlighted that 48% of pharmacists and 36% of doctors said shortages may have resulted in their patients receiving ‘moderate medical treatment’.
Although the group admitted that ‘some shortages are impossible to prevent’ it added that ‘good preparation and early warning would, in our view, help to minimise the impact’.
The group has also asked for a meeting with the Minister of State for Community and Social Care, Alistair Burt, in order to ‘discuss these findings in more detail and to consider actions that would improve the situation for patients and healthcare professionals’.
Related articles
Drug shortage woes continue in the UK
Members of parliament to hold inquiry into UK drug shortages
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2016 Pro Pharma Communications International. All Rights Reserved.
Source: APPG, Chemist and Druggist
Guidelines
Regulatory update for post-registration of biological products in Brazil
New regulations in Brazil for the registration of biosimilars
Policies & Legislation
NPRA Malaysia trials new timelines for variation applications
Regulatory evolution and impact of simplified requirements for interchangeable biosimilars in the US
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Meitheal expands portfolio with three biosimilars through exclusive US licensing agreement
EMS proposes merger with Hypera to form Brazil's largest drugmaker
Bio-Thera and Gedeon Richter partner to commercialize Stelara biosimilar BAT2206
Advances for Biocon Biologics’ Stelara and Eylea biosimilars
Comments (0)
Post your comment